A New Paradigm in the Treatment of Gastric Cancer

*Abdul Rahman El Kinge
Division of Hematology / Oncology, Specialized Medical Center, Saudi Arabia
Submission: November 23, 2016; Published: December 06, 2016
*Corresponding author: Abdul Rahman El Kinge, Division of Hematology / Oncology, Specialized Medical Center, King Fahd Road, Riyadh 11586, KSA, Saudi Arabia.

Abstract
Gastric Cancer (GC) is the fourth common cancer worldwide. It has a geographical distribution affecting mainly the developing countries much more than the developed ones. It is an aggressive disease with poor outcome. Little breakthroughs were achieved in the treatment of GC in the last few decades. These were confined to chemotherapy and surgical techniques. The development of gastric cancer is a complex, multistep process, which involves multiple genetic and epigenetic alterations. The previous classifications of GC had limited impact on its management and prognosis. A novel molecular classification will enhance our understanding of the cancer of the stomach and it will individualize our therapy in a targeted manner for more robust results and better prognosis.

According to The Cancer Genome Atlas Project (TCGA), GC has been recently divided into 4 categories according to the molecular imprint specification. These 4 subtypes are Epstein-Barr virus positive tumors (EBVp), microsatellite instability tumors (MSI), genomically stable tumors (GS) and tumors with chromosomal instability (CIN). There is an immense diversity in the pathways where targeted and immunotherapeutic agents could treat gastric cancer. We propose a possible new treatment approach against gastric cancer guided by its genetic fingerprint.

Keywords: Gastric cancer; Treatment; Classification; Genomic mapping

Introduction
Gastric cancer (GC) was the fourth most common type of cancer and the third leading cause of cancer-related death worldwide in 2012 [1]. It has a greater incidence among the developing countries which is attributed to the different preventive health measures carried out by their developed counterparts [1]. In the United States, it represents only 1.6% of all cancers [2]. For the past few decades, clinicians used mainly Lauren’s classification of GC in their practice, where GC is divided into 2 main types, intestinal and diffuse [3]. Both types have almost similar lifestyle and environmental risk factors but the latter exhibits more a genetic foundation. But this classification has limited clinical value with little effect on the course of therapy.

With the modern advances in molecular profiling, it is possible now to have a better understanding of the genetic pathophysiology of primary gastric carcinoma. Molecular profiling would shape a more comprehensive vision on the optimal classification in order to tailor well individualized therapies for GC patients [4,5]. In this regard, The Cancer Genome Atlas Project (TCGA) developed a novel genomic classification of GC. They divided GC into four different genomic tumors: Epstein-Barr virus (EBV) positive tumors (EBVp), microsatellite instability tumors (MSI), genomically stable tumors (GS) and tumors with chromosomal instability (CIN) [4,6]. These 4 subtypes have such distinctive genetic features that they might be considered as totally separate entities.
The first group of tumors is Epstein-Barr virus positive gastric cancer (EBVpGC) [4]. EBV positivity, which represents 9% of the cases, is a good prognostic factor in resected GC [4,7]. The chief molecular signature of this group is 5’cytosine—phosphate—Guanine3’ (CpG) island promoter methylation of GC related genes [8]. The latent membrane protein 2A (LMP2A) expression of EBV may promote Deoxyribonucleic acid (DNA) methylation through inducing signal transducer and activator of transcription 3 (STAT3) phosphorylation and subsequent transcription of DNA methyltransferase 1 (DNMT1) [9]. DNA hypermethylation are greatly upregulated in EBVpGCs compared to the other groups. Both promoter and non-promoter CpG islands are expressed in EBV-associated DNA hypermethylation.

Interestingly, Cyclin-dependent kinase inhibitor 2A (CDKN2A) promoter hypermethylation was displayed in all EBVpGCs, while mutL homolog 1 (MLH1) hypermethylation was not recorded [4]. On the other hand, there is a clear expression of the phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic subunit alpha (PI3K CA) mutation in EBVpGCs; in addition, 55% had AT-rich interactive domain 1A (ARID1A) mutation and 23 % bore the BCL6 corepressor (BCOR) mutation, but they have hardly ever shown a TP53 mutation. Moreover, multiple new amplification locus for janus kinase 2 (JAK2), CD274, and programmed cell death 1 ligand and 2 (PD-L1/2) were detected repeatedly in EBVpGCs. JAK2 is used by several class I cytokine receptor to activate STAT to regulate gene transcription. As for PD-L1/2 and their receptors PD-1/2, they are involved in immune checkpoints [4,6].

From the above TCGA findings, many potential therapeutic pathways have been made possible to target EBVpGC. The novel therapies should be directed against the high expression of PD-L1 and PD-L2, JAK2 amplification and PI3K CA mutation either by direct inhibition, or alternative mechanism through mTOR and PKB [10]. Many agents are currently under clinical trials involving the checkpoint inhibitors. The second category is the MSI GC. It forms 21% of all GCs with positive prognostic marker in resected GCs [10,11]. MSI is recognised as an early event in GC tumorigenesis [12]. It is caused by extensive replication errors in simple repetitive microsatellite sequences due to the defects in mismatch repair genes, mainly in the major histocompatibility complex class I gene (MHC I).

According to TCGA, MSI subtype was characterized by accumulation of different mutations in PIK3CA, human epidermal growth factor receptor (HER) 3, HER2, and epidermal growth factor receptor (EGFR), with an increase in the numbers of tumor specific neoantigens [6]. The favorable targetable pathways for this group are immunotherapy which is related to the elevated numbers of tumor specific neoantigens and MHC class I aberrations, drugs directed against HER3, Kirsten rat sarcoma viral oncogene homolog (KRAS), HER2, EGFR and PIK3CA mutation either by direct inhibition or alternative mechanism through mTOR and PKB [10]. Trastuzumab, an HER2 monoclonal antibody, is one example where it showed better overall survival when it was combined with chemotherapy in patients with HER2 over expressed metastatic GC [13].

The third group is CIN and it is the largest making 50% of all GCs. CIN is due to the imbalanced division of chromosomes to daughter cells upon mitosis and results in the loss or gain of DNA during cell division [14]. Copy number gains at 8p, 12q, 13q, 17q, and 20q and copy number losses at 3p, 4q, 5q, 15q, 16q, and 17q are frequently noted in GCs [15-18]. CIN is involved in focal gene amplifications as well as to chromosomal gains and losses. The main findings in CIN were genomic amplifications of genes that encode receptor tyrosine kinases (RTK), elevated phosphorylation of EGFR which consistent with amplification of EGFR, and amplifications of cell cycle genes Cyclin E1 (CCNE1), Cyclin D1 (CCND1), and Cyclin-dependent kinase 6 (CDK6) [4,6].

The CIN subtype was studied abundantly in clinical trials over the past decade due to the numerous available targetable pathways. The majority of agents are aimed at the RTK gene amplifications, including HER2, EGFR, mesenchymal epithelial transition factor (MET), fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor A (VEGFA) [10]. Ramucirumab, a human VEGF receptor 2 antagonist, has shown significant improvement in overall survival in patients with recurrent or progressive gastric and gastro-esophageal junction cancer after primary treatment with platinum or fluoropyrimidine combination chemotherapy, either as a single agent or in combination with paclitaxel [19].

The Authors of TCGA describe a fourth group which is the GS tumors. It constitutes 20% of GCs [10]. This group has an upregulated ras homolog family member A (RHOA) mutation in 15% of the cases. The role of RHOA in cell motility points out the contribution of RHOA modification to altered cell adhesion in the carcinogenesis of GCs. Interestingly, they found mutations in cadherin 1 (CDH1) which underlie a hereditary pattern with an inferior outcome. Other genetic abnormalities have been noted such as a recurrent interchromosomal translocation between claudin 18 (CLDN18) and Rho GTPase-activating protein 6 (ARHGAP26) [6]. As such, many therapeutic options can be studies in this subtype to target different promising pathways such as the RHOA dysregulation, FGFR, VEGF-A and PIK3CA mutation by either direct inhibition, or alternative mechanism through mTOR and PKB [10]. Many agents are currently under clinical phase I and II trials with little evidence yet to show.

It is worth noting that outside the new TCGA classification, angiogenesis stands almost alone as a plausible target. With much evidence, the high manifestation of the proangiogenic VEGF was associated with an inferior overall survival in gastric cancer patients. VEGF-A was seen as a major indicator of the risk of bone marrow metastasis, while VEGF-D is considered as a valuable predictor of the lymphatic metastasis in gastric cancer patients.
cancer patients. It would be vital to recognize the expression of the different VEGF family members in the primary GC tumor in order to establish the risk of distant metastasis and the benefit of anti-VEGF therapy [20-21].

Conclusion

Despite the advances in molecular genomics in the recent years, the exact mechanisms underlying gastric cancer tumorigenesis are still not yet completely reached. The necessity to overcome its aggressive nature and its dim outcome is of utmost importance by means of novel treatment options. TCGA has offered a new molecular classification of GC that paved the way to a more explicit categorization of the different genotypic entities of GC. The findings would delineate a road map for the many potential specific targeted pathways for the treatment of GC. A few drugs have shown good evidence in treating GC, but we are far behind attaining a cure in the metastatic setting. While the basis of the development of GC is complex and multifactorial, our therapy should be a combination of different targeted or immunotherapeutic agents designed by using the most recent genomic backbone of GC tumors.

References

1. Lindsey A Torre, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, et al. (2015) Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 65(2): 87-108.
2. http://seercancer.gov/statfacts/html/stomach.html, accessed June 1, 2016.
3. Hu B, El Hajj N, Stürl S, Lammert N, Barnes R, et al. (2012) Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol 3(3): 251-261.
4. The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517): 202-209.
5. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JI, et al. (2015) Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 21(5): 449-456.
6. Chen T, Xu XY, Zhou PH (2016) Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer 35: 49.
7. Camargo MC, Kim WH, Chianavalli AM, Kim KM, Corvalan AH, et al. (2014) Improved survival of gastric cancer patients with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 63(2): 236-243.
8. Tan P, Yeoh KG (2015) Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastronenterology 149(5): 1153-1162.
9. Kaneda A, Matsusaka K, Aburatani H, Fukayama M (2012) Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 72(14): 3445-3450.
10. Elisa Fontana, Elizabeth C Smyth (2016) Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol 8(2): 113-125.
11. Choi YY, Bae JM, An JY, Kwon IG, Cho I, et al. (2014) Is microsatellite instability a prognostic marker in gastric cancer? a systematic review with meta-analysis. J Surg Oncol 110(2): 129-135.
12. Oda S, Zhao Y, Maehara Y (2005) Microsatellite instability in gastrointestinal tract cancers: a brief update. Surg Today 35(12): 1005-1015.
13. FDA approved label Trastuzumab Manufactured by Genentech, Inc. U.S. Last updated October 2010.
14. Chen T, Sun Y, Ji P, Kopetz S, Zhang W (2015) Topoisomerase Iα in chromosome instability and personalized cancer therapy. Oncogene 34(31): 4019-4031.
15. Kokkola A, Monni O, Poulakakis P, Larramendy ML, Victorzon M, et al. (1997) 17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer 20(1): 38-43.
16. Wu MS, Chang MC, Huang SP, Tseng CC, Sheu JC, et al. (2001) Correlation of histologic subtypes and replication error phenotype with comparative genomic hybridization in gastric cancer. Genes Chromosomes Cancer 30(1): 80-86.
17. Weiss MM, Kuipers EJ, Postma C, Snijders AM, Pinkel D, et al. (2004) Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 26(5-6): 307-317.
18. Tsukamoto Y, Uchida T, Karkan S, Noguchi T, Nguyen LT, et al. (2008) Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. J Pathol 216(4): 471-482.
19. FDA approved label Cyramza (Ramucirumab). Manufactured by Eli Lilly and Company, USA. Last updated April 2014.
20. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, et al. (2008) Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15(1): 69-79.
21. Gretschel S, Astrosini Ch, Vieth M, Jöns T, Tomov T, et al. (2008) Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients. Eur J Surg Oncol 34(6): 642-647.